Skip to content
CancerIndex

Publication

BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.

Authors not recorded

Lab Med2019PMID 30938769stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
30938769
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
ABL1 Fusion1
DasatinibB Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-LikePredictiveCSupports Sensitivity Response1accepted
EID7292

A 16-year-old Caucasian boy was diagnosed with B-lymphoblastic leukemia (B-ALL). Karyotype showed an abnormal clone characterized by the t(3;9)(p13;q34.1). This translocation has been shown previously… (full text at CIViC)

PMID 30938769 · Yenamandra et al., 2019 · Open in CIViC

civic